33.42

0.13% 0.08

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $33.42, with a volume of 68,357. It is up +0.13% in the last 24 hours and up +4.47% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$33.50

Open:

$33.72

24h Volume:

68,357

Relative Volume:

0.06

Market Cap:

$1.94B

Revenue:

$11.13M

Net Income/Loss:

$-105.04M

P/E Ratio:

-14.81

EPS:

-2.2565

Net Cash Flow:

$-81.54M

1W Performance:

-1.28%

1M Performance:

+4.47%

6M Performance:

+439.31%

1Y Performance:

+225.68%

1-Day Range:

$33.35

$34.34

1-Week Range:

$30.82

$34.64

52-Week Range:

$4.30

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

(310) 358-3200

Address

10865 ROAD TO THE CURE, SAN DIEGO, CA

Employee

231

Twitter

@Capricor

Next Earnings Date

2026-05-12

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	33.48	1.94B	11.13M	-105.04M	-81.54M	-2.2565
VRTX Vertex Pharmaceuticals Inc	422.03	109.34B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	705.53	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	792.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.46	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	294.75	33.02B	5.36B	287.73M	924.18M	2.5229

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Initiated	Alliance Global Partners	Buy
Jun-26-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	Roth Capital	Buy
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

May 04, 2026

CAPR stock in focus: Ex-exec eyed for FDA role says drug approvals are not 'best-in-class' signals - MSN

May 04, 2026

Biotech Capricor pairs Q1 results with a corporate update May 12 - Stock Titan

May 04, 2026

Capricor (NASDAQ: CAPR) EVP sells 25K shares under 10b5-1 plan - Stock Titan

May 04, 2026

Capricor (NASDAQ: CAPR) CFO exercises options, sells 25,000 shares under 10b5-1 plan - Stock Titan

May 04, 2026

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - marketscreener.com

May 04, 2026

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data ReleaseWhat's Changed - Sahm

May 04, 2026

CAPR Stock In Focus: Ex-Exec Eyed For FDA Role Says Drug Approvals Are Not ‘Best-In-Class’ Signals - Stocktwits

May 04, 2026

May 01, 2026

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 6.5%What's Next? - MarketBeat

May 01, 2026

Apr 29, 2026

Moody Aldrich Partners LLC Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat

Apr 29, 2026

CAPR Forecast, Price Target & Analyst Ratings | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill

Apr 29, 2026

Apr 27, 2026

Top 10 healthcare stocks by forward P/E: From Capricor's 418x to Alignment Healthcare's 48x - MSN

Apr 27, 2026

Apr 26, 2026

Understanding the Setup: (CAPR) and Scalable Risk - Stock Traders Daily

Apr 26, 2026

CAPR stock draws investor attention after AAN presentation for DMD therapy - MSN

Apr 26, 2026

Assessing Capricor Therapeutics (CAPR) Valuation After HOPE-3 Phase 3 Data And BLA Review Progress - Sahm

Apr 26, 2026

Apr 24, 2026

How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Yahoo Finance

Apr 24, 2026

We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn - Yahoo Finance

Apr 24, 2026

Roth Capital Maintains Capricor Therapeutics (CAPR) Buy Recommendation - MSN

Apr 24, 2026

Apr 23, 2026

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting - Sahm

Apr 23, 2026

CAPR (Capricor Therapeutics Inc.) reports wider than expected Q4 2025 loss, stock notches small gain in daily trading. - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

CAPR (Capricor Therapeutics Inc.) reports wider Q4 2025 loss than estimates, shares dip 1.28% in today's trading.Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

CAPR (Capricor Therapeutics) EV-to-OCF : -24.77 (As of Apr. 28, 2026) - GuruFocus

Apr 22, 2026

Capricor Therapeutics Announces Late-Breaking Presentation - GlobeNewswire

Apr 22, 2026

How Investors May Respond To Capricor Therapeutics (CAPR) HOPE-3 Data and Pending FDA Decision - Sahm

Apr 22, 2026

Apr 20, 2026

Capricor (CAPR) Stock: Why Margin Expansion (Extends Gains) 2026-04-20Expert Breakout Alerts - UBND thành phố Hải Phòng

Apr 20, 2026

Apr 17, 2026

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits

Apr 17, 2026